Genetic Technologies Limited (GENE)
Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
Industry • Biotechnology & Pharmaceuticals |
Sector • Healthcare |
company reported third quarter of 2019 operating loss of $0 millions
Published Nov 30 -0001
CSIMarket Team / CSIMarket.com
For the fiscal time-frame ending 0 company reached break-even of $0.00 per share compare to $0.00 a year before and from $0.00 per share from the previous reporting season.
Revenues remained unaltered to $0.00 millions from $0.00 millions in the comparable reporting season a year before and sequentially from $0.00 millions.
Genetic Technologies Limited reported unchanged a shortfall of $0.000 million, in the fiscal time-frame ending 0, from a year ago.
Genetic Technologies Limited is expected to report next financial earnings on August 29, 2023.
Revenues remained unaltered to $0.00 millions from $0.00 millions in the comparable reporting season a year before and sequentially from $0.00 millions.
Genetic Technologies Limited reported unchanged a shortfall of $0.000 million, in the fiscal time-frame ending 0, from a year ago.
Genetic Technologies Limited is expected to report next financial earnings on August 29, 2023.